University of Essex Researchers Create Microscopic Medicines for Neurodegenerative Diseases

Researchers at the University of Essex have developed innovative microscopic medicines that may transform the treatment of neurodegenerative diseases, including Alzheimer’s, Parkinson’s disease, and motor neurone disease (MND). The team collaborated with international experts, employing artificial intelligence to design tiny antibody fragments capable of being produced directly within human cells.

These newly engineered fragments, termed intrabodies, differ significantly from conventional antibodies that primarily operate outside cells. Intrabodies are stabilized for intracellular use, allowing them to effectively target disease-related proteins.

Key Findings on Stability

The study, funded by the MND Association and led by Dr. Caitlin O’Shea and Dr. Gareth Wright from the School of Life Sciences, identified electrical charge as crucial in maintaining the stability and functionality of antibody fragments within cells. By combining this insight with AI-driven protein redesign, the researchers successfully transformed 672 different antibodies into intrabodies designed to target important proteins associated with neurodegenerative conditions.

After the publication of their findings in Nature Communications, the redesigned molecules will be made publicly accessible for other scientists, encouraging further research in the field.

Dr. O’Shea, the study’s lead author, remarked, “We looked at the properties of millions of antibodies and compared them with human proteins found inside the cell. From this we figured out that antibodies usually have the wrong charge to exist inside cells without sticking together. We used software developed by Nobel Prize winner David Baker and his group to redesign our antibody fragments, so they had the right charge and are super stable.”

Potential for Future Therapeutics

The researchers are optimistic that their findings could enable the repurposing of a vast array of antibodies developed over decades of biomedical research, facilitating their use as powerful laboratory tools and potentially establishing a foundation for new treatments targeting disease-causing proteins.

Dr. Wright, who directed the research, emphasized the approach’s broader implications for millions affected by neurodegenerative diseases. He stated, “We’ve made intracellular antibodies that stick to proteins that cause neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Huntington’s, and motor neurone disease.” He noted that these conditions can lead to significant cognitive and motor decline, affecting over one million people in the UK and representing a major public health concern.

Encouragement from the MND Association

The MND Association praised the research, underscoring its potential for advancing future treatment options. Dr. Brian Dickie, the charity’s Chief Scientist, expressed optimism, stating, “Dr. Wright and his colleagues have made a significant advance in overcoming one of the key challenges that has impeded the development of antibodies as treatments for neurodegenerative diseases, such as MND. Their research findings provide optimism that a combination of this novel ‘intrabody’ science with emerging gene therapy techniques may lead to new therapeutic strategies that can hit specific molecular targets within neurones.”